Bioanalytical Testing Services Market Size, Share, Growth 2026- 2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
Bioanalytical Testing Services Market Overview
The global bioanalytical testing services market was valued at USD 5.33 billion in 2025 and is projected to register a CAGR of 9.70% from 2026 to 2034. Increasing R&D investments in biopharmaceuticals boost the market growth. Moreover, the increasing adoption of artificial intelligence (AI) and machine learning (ML) in bioanalytical testing services propels the industry growth.
Market Statistics
Key Takeaways
- North America dominated the global revenue with 48.2% share in 2025. The rising R&D investments in new drug development contributed to this dominance.
- The Asia Pacific bioanalytical testing services industry is expected to register the highest CAGR of 13.2% from 2026 to 2034. The growth is attributed to the rise in pharmaceutical and biotechnology activities in the region.
- The United States accounted for the largest share of 55.10% in the North American bioanalytical testing services market, driven by increasing demand for biopharmaceutical products.
- In 2025, the bioavailability segment dominated the market with 35.4% revenue share. Bioavailability plays a crucial role in assessing the effectiveness of a new drug's pharmacokinetic profile after administration in clinical trials.
- The sample preparation segment dominated the market in 2025 with 38.03% share, owing to its selectivity, convenience, speed, and extraction phase configurations.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- Rising expansion of contract research organizations (CROs) drives the industry growth.
- Increasing focus on technological advancements in bioanalytical instruments, such as automated sample preparation and parallel LC separation, propel the market demand.
- The high costs of testing and the lack of skilled professionals hinder the market growth.
- Growing investments in research and development in the pharmaceutical industry are expected to provide lucrative opportunities during the forecast period.
AI Impact on Bioanalytical Testing Services Market
- The integration of artificial intelligence (AI) technology has led to enhanced data extraction and analysis. It provides a precise understanding of the chemical components of biological samples, leveraging AI algorithms.
- AI enables predictive modeling, drug target identification, drug screening, and image screening.
- AI-powered robotics streamlines sample preparation and analysis. It helps reduce the risks of manual errors and turnaround times.
To Understand More About this Research: Download Sample Report
What are Bioanalytical Testing Services?
Bioanalytical testing services analyze biological samples to quantify substances, assess drug efficacy, and ensure safety. They utilize advanced techniques to support drug development, clinical trials, and personalized medicine. The bioanalytical testing services market is experiencing robust growth driven by technological advancements, including chromatography, mass spectrometry, and immunoassays, which are extensively utilized in clinical trial protocols
Bioanalytical Testing vs Analytical Testing
| Parameters | Bioanalytical Testing | Analytical Testing |
| Biological Sample Focus | Analyzes biological matrices, including blood, plasma, serum, urine, tissues, and cell cultures, to measure drugs, metabolites, and biomarkers. | Focuses on chemical substances, raw materials, APIs, excipients, and finished pharmaceutical formulations. |
| Testing Complexity | Highly complex due to variability in biological samples, matrix interference, biomarker detection, and low analyte concentrations. | Comparatively less complex. Testing is conducted on controlled chemical compositions and standardized materials. |
| Regulatory Standards | Requires strict compliance with regulatory guidelines from agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency for pharmacokinetics, bioavailability, and bioequivalence studies. | Governed by pharmacopeial and quality-control standards focused on product purity, stability, and manufacturing consistency. |
| Instrumentation | Uses advanced technologies including LC-MS/MS, ligand-binding assays, flow cytometry, immunoassays, and biomarker analysis platforms. | Commonly relies on HPLC, GC, spectroscopy, titration systems, and chromatography instruments for chemical characterization. |
| Applications in Drug Development | Essential for pharmacokinetic (PK), pharmacodynamic (PD), ADME, biomarker studies, immunogenicity testing, and clinical trial sample analysis. | Widely used for raw material testing, impurity profiling, formulation development, stability testing, and quality assurance in manufacturing. |
| Data Interpretation | Requires complex statistical and biological interpretation due to patient variability and biomarker interactions. | Primarily focuses on chemical composition, purity, and quantitative analysis with standardized interpretation methods. |
| Outsourcing Demand | Frequently outsourced to CROs and specialized bioanalytical laboratories due to high expertise and regulatory requirements. | Often performed both in-house and through analytical service providers for routine quality and formulation testing. |
| Role in Precision Medicine | Plays a critical role in biologics, biosimilars, gene therapy, and personalized medicine development. | Supports formulation optimization and manufacturing quality rather than individualized therapeutic monitoring. |
There is a rising demand for well-equipped laboratories offering services for bioanalytical investigations involving small molecules in a variety of matrices, such as tissues, blood, serum, and plasma, to meet patient demands and enhance patient outcomes. This encourages the construction of new bioanalytical labs and facilities with highly skilled professionals.
For instance, in September 2023, Eurofins established a biopharma services campus in India's Genome Valley to provide services to international pharmaceutical corporations in the areas of formulation development, safety toxicology, bio-analytical services, and discovery chemistry and biology.
Bioanalytical Testing Services Market Trends
Rising Expansion of Contract Research Organizations (CROs) Drives Market Growth
The market growth rate for bioanalytical testing services is being fueled by the increasing expansion of CROs. They aim to provide efficient, accelerated, and personalized clinical trial solutions that meet the unmet research and development needs of pharmaceutical and biotech companies worldwide.
For instance, in July 2024, Harvest Integrated Research Organization (HiRO) acquired CRO DeltaMed Solutions as part of its ongoing efforts to expand its cross-border operations in the US. The acquisition will help HiRO harness the expertise of both organizations in key therapeutic areas and service offerings while also improving its capability.
Rising Technological Advancements in Bioanalytical Instruments
The bioanalytical testing services market is experiencing significant growth, driven by the rising need for technologically advanced bioanalytical instruments to meet the demands of scientists, research and development centers, and healthcare professionals.
HPLC-MS, an essential bioanalytical instrument, is constantly witnessing technological advancements in areas like automated sample preparation and parallel LC separation to improve the efficiency and detection of diseases among patients. This, in turn, drives the bioanalytical testing services market revenue.
For instance, in December 2023, HPLC-MS combined the mass spectral selectivity of MS with the separation capability of LC to generate great throughput, sensitivity, and selectivity in the pharmaceutical sector for both in vitro and in vivo applications.
Challenges in Bioanalytical Testing Services Market
- Stringent Regulatory Requirements: Bioanalytical laboratories must comply with strict global regulatory guidelines. Adherence to these requirements increases validation and documentation burdens.
- High Instrumentation Costs: Advanced technologies such as LC-MS/MS, flow cytometry, and immunoassay platforms require high capital investment and maintenance expenses. Such high costs hinder the market growth.
- Data Integrity Concerns: Increasing digitalization leads to the growing data privacy and security concerns.
- Skilled Workforce Shortages: The market experiences a shortage of trained professionals. They lack expertise in bioanalytical methods, regulatory compliance, and advanced instrumentation.
- Operational and Compliance Costs: Maintaining GLP/GMP-compliant facilities and quality systems raises operational expenditures for service providers.
Bioanalytical Testing Services Market Segment Insights
Bioanalytical Testing Services Test Insights
The global bioanalytical testing services market segmentation, based on test, includes ADME, PK, PD, bioavailability, bioequivalence, and others. In 2024, the bioavailability segment dominated the market for bioanalytical testing services. Bioavailability plays a crucial role in assessing the effectiveness of a new drug's pharmacokinetic profile after administration in clinical trials.
Moreover, there has been a rise in the number of ongoing clinical trials. Therefore, integrating bioavailability testing into these trials is essential to ensure consistency and stability between formulations used, ultimately improving patient outcomes.
For instance, according to a report published in February 2023 by the WHO International Clinical Trials Registry Platform (ICTRP), in 2022, the Western Pacific region has seen a significant rise in clinical trial registrations per year. This increase is mainly attributed to the high number of clinical trial registrations in China and Japan, ranking first and second in the region, respectively.
Bioanalytical Testing Services Workflow Insights
The global bioanalytical testing services market segmentation, based on workflow, includes sample analysis, sample preparation, and others. The sample preparation segment dominated the market owing to its selectivity, convenience, speed, and extraction phase configurations. Technology oriented sample preparations are being developed to meet the increasing need for automation, reduced solvent usage, and miniaturization, leading to on-site, in situ, and in vivo applications.
For instance, in November 2023, Thermo Fisher Scientific launched automated sample preparation solutions for laboratories that are approved for in vitro diagnostic (IVD) and in vitro diagnostic regulation (IVD-R). The new solutions will help streamline and automate respiratory diagnostic testing.
Global Bioanalytical Testing Services Market, Segmental Coverage, 2020 - 2034 (USD billion)
Source: Secondary Research, Primary Research, PMR Database and Analyst Review
Bioanalytical Testing Services Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominated the bioanalytical testing services market with 48.2% share owing to the rising R&D investments in new drug development. Also, the rise in the expansion of pharmaceutical companies in the North American region is propelling market growth.
For instance, in May 2024, Mercodia expanded its bioanalytical testing services in the United States. This expansion will enhance the company’s ability to offer bioassay testing for preclinical and clinical programs, thus increasing Mercodia’s regional and global footprint.
Moreover, the United States accounted for the largest share of 55.10% in the North American bioanalytical testing services market, driven by increasing demand for biopharmaceutical products, the need for specialized tests such as electrophoresis, electrochemical assays, and immunoassays, and other cutting-edge medications in this region.
Global Bioanalytical Testing Services Market Regional Coverage, 2020 - 2034 (USD billion)
Source: Secondary Research, Primary Research, PMR Database and Analyst Review
The Asia-Pacific bioanalytical testing services market is expected to grow at the fastest CAGR of 13.2% from 2026 to 2034 attributed to the rise in pharmaceutical and biotechnology activities in Asia Pacific region. Further, the increase in healthcare spending, rising investments, and acquisitions from companies in developed nations to improve regional healthcare are driving the market growth.
For instance, in November 2023, Resolian, an international bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, acquired Denali Medpharma, a prominent bioanalytical CRO based in China. The acquisition will enable Resolian to expand clinical trials to nearly any location without the need to switch bioanalytical CROs.
Moreover, China’s bioanalytical testing services market held the largest market share in the Asia Pacific region over the forecast period, driven by the rising demand for bioanalytical testing services to cater to the large population and diverse patient demographics.
Bioanalytical Testing Services Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the bioanalytical testing services market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market environment, the bioanalytical testing services industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global bioanalytical testing services industry to benefit clients and increase the market sector. In recent years, the bioanalytical testing services industry has witnessed some technological advancements. Major players in the bioanalytical testing services market include Charles River Laboratories International, Covance, Inc., ICON Plc., Intertek Group Plc., IQVIA, Labcorp (Toxikon), Pace Analytical Services LLC, SGS SA, Syneos Health and Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. offers a wide range of specialty diagnostics, life sciences solutions, laboratory products, analytical instruments, and biopharma services. The Analytical Instruments division provides a broad portfolio of consumables, instruments, software, and services for use in biotechnology, pharmaceutical, academic, environmental, government, and other research and industrial markets, as well as clinical laboratories. For instance, in February 2024, Thermo Fisher Scientific Inc. extended its good manufacturing practices (GMP) facility in the United States to include mycoplasma and biosafety testing capabilities. This analytical testing service will help clients to provide safe medications to patients.
SGS SA is an inspection, testing, and certification company. The company provides a wide range of services, including testing, verification, training, and certification, to help customers reduce risk, access new markets, control quality and quantity, and ensure regulatory compliance for their products, processes, and systems. SGS SA has an operating network of laboratories and 2,600 offices across 116 countries. For instance, in September 2021, SGS officially declared the expansion of their bioanalytical testing facility in France, incorporating a new 800-m2 structure. This development will enable SGS SA to facilitate the advancement of small molecules, peptides, biotherapeutics, as well as cell and gene therapies to effectively address the increasing need for bioanalytical testing services.
Key companies in the bioanalytical testing services market include:
- Charles River Laboratories International
- Covance, Inc.
- ICON Plc.
- Intertek Group Plc.
- IQVIA
- Labcorp (Toxikon)
- Pace Analytical Services LLC.
- SGS SA
- Syneos Health
- Thermo Fisher Scientific Inc.
Bioanalytical Testing Services Industry Developments
May 2026: SGS acquired Keystone Bioanalytical, a bioanalytical testing service provider based in Philadelphia, U.S. With this acquisition, SGS aims to strengthen end-to-end drug development lifecycle testing capabilities for pharma and biotech industries in North America. (Source: PRNewswire)
February 2026: Eurofins Viracor BioPharma Services announced the addition of enhanced bioanalytical testing capabilities. These new services are aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP). (Source: BUSINESS WIRE)
Bioanalytical Testing Services Market Segmentation:
Bioanalytical Testing Services Molecule Outlook
- Small Molecule
- Large Molecule
- LC-MS Studies
- Immunoassays
- PK
- ADA
- Others
- Others
Bioanalytical Testing Services Test Outlook
- ADME
- In-Vivo
- In-Vitro
- PK
- PD
- Bioavailability
- Bioequivalence
- Others
Bioanalytical Testing Services WorkFlow Outlook
- Sample Analysis
- Hyphenated technique
- Chromatographic technique
- Electrophoresis
- Ligand Binding Assay
- Mass Spectrometry
- Nuclear Magnetic Resonance
- Sample Preparation
- Protein Precipitation
- Liquid-Liquid Extraction
- Solid Phase Extraction
- Others
- Others
Bioanalytical Testing Services Application Outlook
- Oncology
- Neurology
- Infectious Diseases
- Gastroenterology
- Cardiology
- Others
Bioanalytical Testing Services End-Use Outlook
- Pharma & BioPharma Companies
- CDMO
- CRO
Bioanalytical Testing Services Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia-Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Bioanalytical Testing Services Report Scope:
| Report Attributes | Details |
| Market Size Value in 2025 | USD 5.33 billion |
| Market Size Value in 2026 | USD 5.98 billion |
| Revenue Forecast in 2034 | USD 12.24 billion |
| CAGR | 9.70% from 2026 – 2034 |
| Base Year | 2025 |
| Historical Data | 2021 – 2024 |
| Forecast Period | 2026 – 2034 |
| Quantitative Units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, region, and segmentation. |
FAQ's
The global bioanalytical testing services market size was valued at USD 5.33 billion in 2025 and will be valued at USD 12.24 billion in 2034
The global market is projected to grow at a CAGR of 9.70% during the forecast period, 2026-2034.
North America had the largest share of 48.2%.
The key players in the market are Charles River Laboratories International, Covance, Inc., ICON Plc., Intertek Group Plc., IQVIA, Labcorp (Toxikon), Pace Analytical Services LLC, SGS SA, Syneos Health and Thermo Fisher Scientific Inc.
The bioavailability category dominated the market in 2025 with 35.4%.
The sample preparation held the largest share of 38.03% in the global market in 2025
Download Sample Report of bioanalytical testing services market
Please fill out the form to request a customized copy of the research report.
